Research progress of dalpiciclib in treatment of breast cancer
10.12092/j.issn.1009-2501.2024.06.014
- VernacularTitle:达尔西利在乳腺癌治疗中的研究进展
- Author:
Caiying DU
1
;
Xianghua QUAN
;
Caihong SUN
;
Haidan YUAN
Author Information
1. 延边大学药学院,延吉 133002,吉林
- Keywords:
dalpiciclib;
cyclin-dependent kinase 4/6;
breast cancer;
clinical trials
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(6):715-720
- CountryChina
- Language:Chinese
-
Abstract:
As the first domestically originated cell cycle protein-dependent kinase 4/6 inhibitor,dalpiciclib has been approved by the State Drug Ad-ministration for the treatment of hormone recep-tor-positive/human epidermal growth factor recep-tor 2-negative advanced or metastatic breast can-cer in combination with fulvestrant or aromatase inhibitors.This article focuses on the progress of dalpiciclib research in breast cancer,summarizing the drug's mechanism of action,phase Ⅰ-Ⅲ clinical trials,and drug safety issues.